Click here to get full coverage on Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PR Newswire

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025  PR Newswire

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PR Newswire

Click here to get full coverage on LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN

LPCN 1154 for postpartum depression continues clinical process after safety review  Contemporary OB/GYN

LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN

Click here to get full coverage on Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?  Yahoo Finance

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan

Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss  Stock Titan

Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan

Click here to get full coverage on Lipocine completes Phase III enrolment for LPCN 1154 in PPD - Clinical Trials Arena

Lipocine completes Phase III enrolment for LPCN 1154 in PPD  Clinical Trials Arena

Lipocine completes Phase III enrolment for LPCN 1154 in PPD - Clinical Trials Arena

Click here to get full coverage on LPCN: Pipeline advanced and cash raised, but revenue dropped and net loss widened in 2025 - TradingView

LPCN: Pipeline advanced and cash raised, but revenue dropped and net loss widened in 2025  TradingView

LPCN: Pipeline advanced and cash raised, but revenue dropped and net loss widened in 2025 - TradingView

Click here to get full coverage on Lipocine: Q4 Earnings Snapshot - whas11.com

Lipocine: Q4 Earnings Snapshot  whas11.com

Lipocine: Q4 Earnings Snapshot - whas11.com

Click here to get full coverage on Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PR Newswire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025  PR Newswire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PR Newswire

Click here to get full coverage on Progress Report: Second Interim Safety Review of Phase 3 Trial of LPCN 1154 in Postpartum Depression - Psychiatric Times

Progress Report: Second Interim Safety Review of Phase 3 Trial of LPCN 1154 in Postpartum Depression  Psychiatric Times

Progress Report: Second Interim Safety Review of Phase 3 Trial of LPCN 1154 in Postpartum Depression - Psychiatric Times

Click here to get full coverage on Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone  PR Newswire

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire

Click here to get full coverage on Enrollment and Dosing Complete in Phase 3 Trial of LPCN 1154 for Postpartum Depression - Psychiatric Times

Enrollment and Dosing Complete in Phase 3 Trial of LPCN 1154 for Postpartum Depression  Psychiatric Times

Enrollment and Dosing Complete in Phase 3 Trial of LPCN 1154 for Postpartum Depression - Psychiatric Times

Click here to get full coverage on Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)  PR Newswire

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire

Click here to get full coverage on Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PR Newswire

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)  PR Newswire

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PR Newswire

Click here to get full coverage on Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)  PR Newswire

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire

Click here to get full coverage on Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)  PR Newswire

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire

Click here to get full coverage on Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PR Newswire

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)  PR Newswire

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PR Newswire

Click here to get full coverage on Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PR Newswire

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®  PR Newswire

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PR Newswire

Click here to get full coverage on Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PR Newswire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025  PR Newswire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PR Newswire

Click here to get full coverage on Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PR Newswire

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology  PR Newswire

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PR Newswire

Click here to get full coverage on Phase 3 Trial of LPCN 1154 for Postpartum Depression Shows Positive Progress - Psychiatric Times

Phase 3 Trial of LPCN 1154 for Postpartum Depression Shows Positive Progress  Psychiatric Times

Phase 3 Trial of LPCN 1154 for Postpartum Depression Shows Positive Progress - Psychiatric Times

Click here to get full coverage on At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan

At-home postpartum depression drug from Lipocine tested in 90 women  Stock Titan

At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan

Click here to get full coverage on Progress Update: LPCN 1154 for the Treatment of Postpartum Depression - Psychiatric Times

Progress Update: LPCN 1154 for the Treatment of Postpartum Depression  Psychiatric Times

Progress Update: LPCN 1154 for the Treatment of Postpartum Depression - Psychiatric Times

Click here to get full coverage on Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada  PR Newswire

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire

Click here to get full coverage on Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Yahoo Finance

Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15  Yahoo Finance

Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Yahoo Finance

Click here to get full coverage on Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PR Newswire

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil  PR Newswire

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PR Newswire

Click here to get full coverage on Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget

Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow?  Bitget

Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget

Click here to get full coverage on First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online

First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial  Patient Care Online

First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online

Click here to get full coverage on Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView

Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77)  TradingView

Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView

Click here to get full coverage on Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 - Clinical Trials Arena

Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154  Clinical Trials Arena

Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 - Clinical Trials Arena

Click here to get full coverage on H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com

H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress  Investing.com

H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com

Click here to get full coverage on Lipocine Stock Quote, Share Price, News and Analysis - Longbridge

Lipocine Stock Quote, Share Price, News and Analysis  Longbridge

Lipocine Stock Quote, Share Price, News and Analysis - Longbridge

Click here to get full coverage on Lipocine Inc expected to post a loss of 61 cents a share - Earnings Preview - TradingView

Lipocine Inc expected to post a loss of 61 cents a share - Earnings Preview  TradingView

Lipocine Inc expected to post a loss of 61 cents a share - Earnings Preview - TradingView

Click here to get full coverage on Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154 - Patient Care Online

Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154  Patient Care Online

Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154 - Patient Care Online

Click here to get full coverage on LPCN Crypto News - Intellectia AI

LPCN Crypto News - Intellectia AI

Click here to get full coverage on Lipocine Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Lipocine Stock Jump Looks Great, But How Secure Is That Gain?  Trefis

Lipocine Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Click here to get full coverage on Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Clinical Trials Arena

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression  Clinical Trials Arena

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Clinical Trials Arena

Click here to get full coverage on LPCN Technical Analysis & Price Forecast - Intellectia AI

LPCN Technical Analysis & Price Forecast  Intellectia AI

LPCN Technical Analysis & Price Forecast - Intellectia AI

Click here to get full coverage on Lipocine Files Prospectus to Enable $50M Stock Offering - TipRanks

Lipocine Files Prospectus to Enable $50M Stock Offering  TipRanks

Lipocine Files Prospectus to Enable $50M Stock Offering - TipRanks

Click here to get full coverage on Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PR Newswire

Lipocine Receives Updated Regulatory Guidance on LPCN 1154  PR Newswire

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PR Newswire

Click here to get full coverage on Lipocine’s PPD drug trial continues after positive safety review - Investing.com

Lipocine’s PPD drug trial continues after positive safety review  Investing.com

Lipocine’s PPD drug trial continues after positive safety review - Investing.com

Click here to get full coverage on Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - Barchart.com

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025  Barchart.com

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - Barchart.com

Click here to get full coverage on Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com

Lipocine completes enrollment in phase 3 trial for PPD treatment  Investing.com

Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com

Click here to get full coverage on LPCN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

LPCN Stock: Price, Forecast, Financials & AI Analysis  Intellectia AI

LPCN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

Click here to get full coverage on Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study - PR Newswire

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study  PR Newswire

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study - PR Newswire

Click here to get full coverage on FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis  PR Newswire

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire

Click here to get full coverage on Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks

Lipocine Advances Phase 3 Trial for PPD Treatment  TipRanks

Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks

Click here to get full coverage on Lipocine Announces FDA Labeling Changes for Testosterone Products - PR Newswire

Lipocine Announces FDA Labeling Changes for Testosterone Products  PR Newswire

Lipocine Announces FDA Labeling Changes for Testosterone Products - PR Newswire

Click here to get full coverage on Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Australia

Lipocine completes patient visits in phase 3 trial for PPD treatment  Investing.com Australia

Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Australia

Click here to get full coverage on Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com

Lipocine reaches 80% enrollment in postpartum depression drug trial  Investing.com

Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com

Click here to get full coverage on Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart

Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline  Minichart

Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart

Click here to get full coverage on Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries  PR Newswire

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire

Click here to get full coverage on Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks

Lipocine Completes Phase 3 Trial for Postpartum Depression  TipRanks

Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks

Click here to get full coverage on Lipocine Inc dovrebbe registrare una perdita di 40 centesimi per azione - Anteprima degli utili - TradingView

Lipocine Inc dovrebbe registrare una perdita di 40 centesimi per azione - Anteprima degli utili  TradingView

Lipocine Inc dovrebbe registrare una perdita di 40 centesimi per azione - Anteprima degli utili - TradingView

Click here to get full coverage on Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada - PR Newswire

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada  PR Newswire

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada - PR Newswire

Click here to get full coverage on Can LPCN scale operations efficiently - Share Buyback & Capital Efficient Trade Techniques - mfd.ru

Can LPCN scale operations efficiently - Share Buyback & Capital Efficient Trade Techniques  mfd.ru

Can LPCN scale operations efficiently - Share Buyback & Capital Efficient Trade Techniques - mfd.ru

Click here to get full coverage on Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart

Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights  Minichart

Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart

Click here to get full coverage on Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 - PR Newswire

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154  PR Newswire

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 - PR Newswire

Click here to get full coverage on Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals - PR Newswire

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals  PR Newswire

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals - PR Newswire

Click here to get full coverage on LPCN: 1154 Results Illuminate Accelerated Pathway - Zacks Small Cap Research

LPCN: 1154 Results Illuminate Accelerated Pathway  Zacks Small Cap Research

LPCN: 1154 Results Illuminate Accelerated Pathway - Zacks Small Cap Research

Click here to get full coverage on FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma

FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia  Contract Pharma

FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma

Click here to get full coverage on Lipocine Inc. (LPCN) reports earnings - qz.com

Lipocine Inc. (LPCN) reports earnings  qz.com

Lipocine Inc. (LPCN) reports earnings - qz.com

Click here to get full coverage on Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs - Clinical Trials Arena

Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs  Clinical Trials Arena

Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs - Clinical Trials Arena

Click here to get full coverage on Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq

Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine  Nasdaq

Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq

Click here to get full coverage on FDA fast tracks Lipocine’s oral androgen receptor agonist for sarcopenia in cirrhosis - Healio

FDA fast tracks Lipocine’s oral androgen receptor agonist for sarcopenia in cirrhosis  Healio

FDA fast tracks Lipocine’s oral androgen receptor agonist for sarcopenia in cirrhosis - Healio

Click here to get full coverage on Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - Stock Titan

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference  Stock Titan

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - Stock Titan

Click here to get full coverage on Lipocine gears up for two pivotal trials in 2023/2024 - Clinical Trials Arena

Lipocine gears up for two pivotal trials in 2023/2024  Clinical Trials Arena

Lipocine gears up for two pivotal trials in 2023/2024 - Clinical Trials Arena

Click here to get full coverage on Oral androgen receptor agonist improves sarcopenia over 52 weeks in men with cirrhosis - Healio

Oral androgen receptor agonist improves sarcopenia over 52 weeks in men with cirrhosis  Healio

Oral androgen receptor agonist improves sarcopenia over 52 weeks in men with cirrhosis - Healio

Click here to get full coverage on LPCN: 1148 Shows Muscle Loss Reversal - Yahoo Finance

LPCN: 1148 Shows Muscle Loss Reversal  Yahoo Finance

LPCN

Price Chart

Key Statistics

Technicals

About LPCN

Latest News

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PR Newswire

LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers